LillyDirect vs. NovoCare: how manufacturer direct-pay actually works — glp1.how · GLP-1 Guides
LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
Both GLP-1 makers now sell their own brand medications straight to cash-paying patients — Lilly through LillyDirect, Novo Nordisk through NovoCare. Here's what these direct-pay channels actually are, how single-dose vials differ from pens, how a flat cash price differs from a savings card, and the problems direct-pay doesn't solve.
Updated Sep 2, 2026Evidence-backed
If your plan won't cover a GLP-1 and you don't want a compounded copy, there's a third door that barely existed two years ago: buying the real, brand-name medication straight from the company that makes it, at a flat cash price. Eli Lilly runs one of these channels, Novo Nordisk runs the other, and they work similarly enough to be confused and differently enough to matter. Here's what each one actually is, and what it can and can't do for you.
What "manufacturer direct-pay" means
Both programs are self-pay pharmacies operated by the drugmaker. You still need a prescription from a licensed clinician, and the product that arrives is the same FDA-approved brand medication a retail pharmacy would dispense — not a compounded version. What's different is the payment path: instead of running through your insurance and a pharmacy benefit manager, you pay the manufacturer a set price and the medication ships to your door.
LillyDirect sells Lilly's own products, most notably Zepbound (tirzepatide) for weight management. NovoCare Pharmacy sells Novo Nordisk's, including Wegovy (semaglutide) for weight management and Ozempic (semaglutide) for type 2 diabetes. In both cases your prescriber sends the script to the manufacturer's pharmacy, you set up an account and pay, and you choose delivery or pickup.
This is one of the legitimate routes covered in our broader guide to pharmacy sources for GLP-1 medications — worth reading if you're weighing direct-pay against compounded or telehealth options. This guide zooms in on just the two manufacturer channels.
The single-dose vial vs. pen distinction
The detail that made direct-pay newsworthy was the single-dose vial. The familiar format is a prefilled pen or autoinjector: you dial a dose and inject, needle included. A single-dose vial is a small glass container holding one week's dose, from which you draw the medication yourself using a separate syringe and needle you have to obtain and handle correctly.
accessdirect-paylillydirectnovocareself-paycost
Was this helpful?
Common questions
Questions people often ask about this topic.
What is manufacturer direct-pay, and is it the real brand medication?
Both programs are self-pay pharmacies run by the drugmaker — LillyDirect by Eli Lilly, NovoCare Pharmacy by Novo Nordisk. You still need a prescription from a licensed clinician, and the product that arrives is the same FDA-approved brand medication a retail pharmacy would dispense, not a compounded version. What's different is the payment path: instead of running through insurance, you pay the manufacturer a set price and the medication ships to you.
What's the difference between a savings card and cash self-pay?
A savings card (or copay card) lowers what you pay when you do have commercial insurance — it knocks down your copay up to a monthly cap and typically excludes anyone on Medicare, Medicaid, or other government coverage. Cash self-pay is a flat price you pay when insurance isn't involved at all, such as when you're uninsured or your plan excludes the drug. The 'pay as little as $X' figures companies advertise can refer to either mechanism, so it's easy to conflate them.
What's the difference between a single-dose vial and a pen?
A prefilled pen or autoinjector lets you dial a dose and inject, needle included. A single-dose vial is a small glass container holding one week's dose, from which you draw the medication yourself using a separate syringe and needle you have to obtain and handle correctly. Lilly leaned into vials to hit lower price points, but the trade-off is real — the vial is cheaper yet asks more of you, and drawing the wrong amount is a recognized source of dosing errors.
Who does direct-pay actually make sense for?
It tends to fit a specific situation: you have no coverage for the drug — uninsured, or a plan that excludes weight-management medication — and you want the genuine brand product rather than a compounded one. For those people it's often the cleanest legitimate cash route. It's less relevant if your insurance already covers the medication at a reasonable copay, since a covered brand prescription is usually cheaper than any cash price.
Evidence: For & Against
Both sides of the topic, so you can weigh the evidence yourself.
5Supporting
Improve this page▾
Lilly leaned into vials to hit lower price points. As of September 2026, LillyDirect's self-pay Zepbound vials run about $299/month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg maintenance doses — with Lilly now pricing its Zepbound KwikPen at the same tiers. Those maintenance prices depend on refilling within 45 days of your last delivery; outside that window the price reverts higher (Lilly lists roughly $499–$699). This LillyDirect cash pricing is a different thing from the Zepbound savings card's "non-covered" tier, which is for people who have commercial insurance that excludes Zepbound and discounts the single-dose pen to about $499/month or the KwikPen to $299–$449/month by dose. Novo's self-pay, by contrast, is built mostly around its pens and its newer oral tablet rather than vials.
The vial's trade-off is real: it's cheaper and sometimes more available, but it asks more of you — measuring the dose, managing sharps, and following instructions precisely. Drawing the wrong amount from a vial is a recognized source of dosing errors, which is one reason this format rewards careful technique.
Savings card vs. cash pay — not the same thing
Both companies offer "pay as little as $X" figures, and it's easy to conflate two different mechanisms.
A savings card (sometimes called a copay card) lowers what you pay when you do have commercial insurance — it knocks down your copay, usually with a monthly cap on how much it covers, and typically excludes anyone on Medicare, Medicaid, or other government coverage. NovoCare, for instance, advertises a savings offer bringing eligible commercially insured patients to as little as $25/month up to a set cap. Our side-by-side guide to every GLP-1 savings card covers the current terms, caps, and eligibility for each drug.
Cash self-pay is a flat price you pay when insurance isn't in the picture at all — you're uninsured, or your plan excludes the drug. That's the LillyDirect vial pricing above, and NovoCare's self-pay figures for Wegovy (its pens have listed around $199 for introductory doses stepping to higher monthly prices, with an oral option near $149 for a limited window) and Ozempic (as of September 2026: $199/month introductory pricing for new patients on the 0.25 mg and 0.5 mg doses, then $349/month for 0.25–1 mg and $499/month for 2 mg). Exact numbers, promotional windows, and eligibility rules change frequently — the manufacturer's site is the only reliable source for what applies to you today, and the figures here are illustrative snapshots, not quotes.
Who this actually helps
Direct-pay tends to make sense for a specific situation: you have no coverage for the drug — uninsured, or a plan that excludes weight-management medication — and you want the genuine brand product rather than a compounded one. For those people it's often the cleanest legitimate cash route, because it ships from the manufacturer's own authorized channel with no question about what's in the vial.
It's less relevant if your insurance already covers the medication at a reasonable copay, since a covered brand prescription is usually cheaper than any cash price. If your denial is the problem, our guide to understanding insurance coverage walks through formularies, prior authorization, and appeals — sometimes fixing the coverage beats paying cash.
What direct-pay doesn't solve
Neither program is a discount on the underlying drug's economics, and it helps to be clear-eyed about the limits.
It's still brand pricing. A few hundred dollars a month is far below list price, but it's not cheap, and it's an ongoing cost for a medication most people take long-term. The lowest advertised numbers often attach to starting doses or limited-time offers, not the maintenance dose you'll settle on.
It doesn't override your insurance. Cash self-pay generally sits outside your plan, so what you spend usually doesn't count toward your deductible or out-of-pocket maximum, and savings cards exclude government-insured patients.
It doesn't guarantee supply or the diagnosis you want. Programs are structured around specific brand-and-indication pairings — LillyDirect's self-pay track is built around Zepbound, while Mounjaro (the same molecule with a diabetes label) runs on separate paperwork; NovoCare splits Wegovy and Ozempic similarly. And availability of particular doses or formats can shift.
The core question is narrow and answerable: do you have coverage, and do you want the brand product? If the answer is "no coverage" and "yes, brand," a manufacturer direct-pay pharmacy is likely your most straightforward legitimate option. If either answer flips, another route probably serves you better.
This is peer information, not medical or financial advice — prices, offers, and eligibility rules change constantly, so confirm the current specifics directly with the manufacturer's pharmacy and your care team before you count on any figure here.
Does paying cash through direct-pay count toward my insurance deductible?
Generally no. Cash self-pay sits outside your plan, so what you spend usually doesn't count toward your deductible or out-of-pocket maximum, and savings cards exclude government-insured patients. It's also still brand pricing — a few hundred dollars a month is far below list price but not cheap, and it's an ongoing cost for a medication most people take long-term. Prices and eligibility rules change frequently, so confirm current specifics with the manufacturer's pharmacy.
↗
(external link)
Novo Nordisk (NovoCare Pharmacy) · Reporting · Strong evidence
(2026)
Official NovoCare page. Self-pay Wegovy: pens ~$199/mo introductory (0.25/0.5 mg first fills through Dec 31 2026) then $349/mo (up to 2.4 mg), $399 HD 7.2 mg; oral ~$149/mo limited window. Separate savings-card offer 'as little as $25/month' up to a cap for eligible commercially insured; excludes government beneficiaries. Prescriber sends script to NovoCare Pharmacy.
Related guides
Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide — Novo Nordisk and Eli Lilly each run manufacturer copay savings cards for their branded GLP-1s — injectable and oral alike — but the rules, prices, and caps differ by drug, and two programs have quietly been discontinued. Here's every current savings card for Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Trulicity, and the new Foundayo pill side by side, plus what's happened to Saxenda and Victoza.
How compounded GLP-1 medications are made — and how that differs from the branded pens — A compounded GLP-1 isn't a knockoff pen off a production line — it's mixed from raw active ingredient at a pharmacy. Here's how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy actually makes the vial, and how all of that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.
How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board — Our sourcing guides keep ending on the same instruction — verify the pharmacy with your state board, the NABP, or FDA's BeSafeRx — without saying how. This is the step-by-step: the free tools each one offers, what red flags to look for, how to pull a pharmacy's license record, and how to check your own pen's lot number against FDA's counterfeit alerts. About five minutes, start to finish.
"Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you — "Research peptides" are GLP-1 drugs — semaglutide, tirzepatide, retatrutide — sold as powder in vials stamped "research use only, not for human consumption." That label is a legal workaround, not a safety statement. Here's where these products come from, what independent testing actually found inside the vials, why the "research" disclaimer doesn't make them regulated or safe, and the documented harms driving a spike in poison-control calls.
How to find and join a GLP-1 clinical trial — A clinical trial can be a route to next-generation GLP-1 treatment — often at no cost, with close monitoring — while contributing to the research. Here's why you might consider one, the honest trade-offs (placebo, time, eligibility), where to search, how to read a listing, what informed consent and screening involve, the questions to ask, and the red flags that mark a fake.
Getting started: how to access GLP-1 medications — From your first conversation with a doctor to a prescription in hand, there are several decision points that shape your path — who prescribes it, what your insurance actually covers, and whether you go with a branded pen or a compounded product. Here's a step-by-step workflow through the whole process.